Divi’s Labs share price was up over 7 percent in the afternoon session on October 4, after experimental antiviral pill Molnupiravir was found to reduce the risk of hospitalisation or death of approximately 50 percent of those most at risk of contracting COVID-19.
Divi’s Labs is Merck’s authorised manufacturer of Molnupiravir. Divi’s Laboratories, which makes the main ingredient of Merck & Co's experimental antiviral pill, reported positive clinical trial results for the drug.
US-based Merck and Ridgeback Biotherapeutics announced that its investigational oral antiviral medicine, Molnupiravir, has significantly reduced the risk of hospitalisation or death of non-hospitalised adult patients with mild-to-moderate COVID-19.
"At the recommendation of an independent Data Monitoring Committee, and in consultation with the US FDA, the recruitment into the study is being stopped early due to these positive results. Merck plans to submit an application for Emergency Use Authorisation (EUA) to the US FDA soon and marketing applications to other regulatory bodies worldwide," the US-based company said in a statement.
Catch all the market action on our live blog
The analysis showed a planned interim analysis of data from phase 3 clinical trials of Molnupiravir demonstrating consistent efficacy across SARS CoV2 variants, Gamma, Delta, and Mu.
The stock was trading at Rs 5,192.85, up Rs 362.10, or 7.50 percent at 14:36 hours. It touched a 52-week high of Rs 5,313.80, which was also its intraday high. Its intraday low was Rs 4,860.
The scrip was trading with volumes of 195,759 shares, compared to its five-day average of 18,415 shares, an increase of 963.03 percent
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
